USPTO 2015–2025 USPTO PatentsView US Corporation

Alnylam Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 287 granted patents across 23 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

287

Total patents granted

CPC technology areas

26.0

Avg claims per patent

+17%

5-year filing velocity

The verdict

Alnylam holds 287 US patents across 23 technology areas, rank #1,451 of 50,000 tracked assignees.

#1,451
of 50,000 US assignees by volume: Top 6%
by Innovation Score (56.4/100): 26.0
avg claims per patent: +17%
filing velocity, last 5 yrs

Portfolio overview

Alnylam Pharmaceuticals, Inc. has been granted 287 US utility patents between 2015 and 2025, placing Alnylam Pharmaceuticals, Inc. at rank #1,451 across all assignees tracked by PlainPatent. This portfolio spans 23 distinct Cooperative Patent Classification (CPC) subclasses, averaging 26.0 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a US Corporation, Alnylam Pharmaceuticals, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Alnylam sits between Julius BLUM Gmbh (288 patents, rank #1,447) and Jiaxing Super Lighting Electric Appliance Co., Ltd (286 patents, rank #1,455) - the closest US assignees by grant volume. The composite Innovation Score of 56.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 155 grants, compared with 132 in the 2015–2019 window, a +17% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Alnylam Pharmaceuticals, Inc.'s 26.0 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while a multi-domain presence across 23 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Alnylam Pharmaceuticals, Inc. against peers pursuing similar technology classes.

Julius BLUM

288
Milliken &

288
National Institut…

288
Nifco

288
Carl Freudenberg…

287
EMD Millipore

287
Tyco Fire Products

287
Alnylam Pharmaceu… ◀

287
Jiaxing Super Lig…

286

What this shows Alnylam holds 287 patents at rank #1,451, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Alnylam

By rank, the assignees closest to #1,451 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Alnylam's primary technology class.

Alnylam's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

56 Top 6% higher than 94% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Alnylam Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	42	14.6%
2016	24	8.4%
2017	17	5.9%
2018	22	7.7%
2019	27	9.4%
2020	25	8.7%
2021	41	14.3%
2022	26	9.1%
2023	18	6.3%
2024	24	8.4%
2025	21	7.3%

Which technologies does Alnylam Pharmaceuticals, Inc. patent most?

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 262

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 210

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 202

C07H - SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 56

C12Y - ENZYMES 32

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 25

C07C - ACYCLIC OR CARBOCYCLIC COMPOUNDS 24

C07F - ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM 24

C07D - HETEROCYCLIC COMPOUNDS 23

C07K - PEPTIDES 17

Y02P - CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS 10

A01K - ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS 6

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 5

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 4

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 3

Top 15 of 23 technology areas

Patent Moat Analysis

Portfolio Volume Moderate

Tech Breadth Multi-domain

Claim Depth Complex

Velocity Growing

Where it ranks

Overall rank by patents

#1,451

Across all tracked assignees

Innovation Score

56.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Alnylam Pharmaceuticals, Inc. hold?

Alnylam Pharmaceuticals, Inc. holds 287 US granted patents filed between 2015 and 2025, spanning 23 technology areas.

What is Alnylam Pharmaceuticals, Inc.'s Innovation Score?

Alnylam Pharmaceuticals, Inc. has an Innovation Score of 56.4 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Alnylam Pharmaceuticals, Inc. focus on?

Alnylam Pharmaceuticals, Inc.'s top technology area is C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA) with 262 patents. The company has filed patents in 23 CPC subclasses total.

Is Alnylam Pharmaceuticals, Inc.'s patent filing rate increasing or decreasing?

Alnylam Pharmaceuticals, Inc.'s recent filing velocity is +17% compared to the prior five-year period. The company is maintaining or growing its patent output.

What does claim depth mean for Alnylam Pharmaceuticals, Inc.'s patents?

Alnylam Pharmaceuticals, Inc.'s patents average 26.0 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.

How is the Alnylam Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Alnylam's 287 grants land it in the top 6% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Alnylam ranks #1,451 of 50,000. Top 50 holders
Most of this portfolio concentrates in C12N - see who else leads that technology area. C12N leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.